Epstein Barr virus antibody reactivity and gastric cancer: A population-based case-control study.

Aged Case-Control Studies Epstein-Barr Virus Infections / complications Female Humans Male Middle Aged Risk Factors Stomach Neoplasms / pathology
Causality Epstein-Barr virus Gastric cancer Multiplex serology

Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
08 2019
Historique:
received: 11 01 2019
revised: 14 05 2019
accepted: 17 05 2019
pubmed: 4 6 2019
medline: 26 3 2020
entrez: 3 6 2019
Statut: ppublish

Résumé

In contrast to the recognized role of Helicobacter pylori in the etiology of non-cardia gastric cancer (GC), there is still insufficient epidemiological evidence for the involvement of Epstein-Barr virus (EBV) in gastric carcinogenesis. We aimed to evaluate the relation of antibody profile and antibody reactivity intensity against four individual EBV proteins to GC risk. We used information from 281 GC cases and 2071 age and sex frequency matched controls recruited in the frame of the MCC-Spain multicase-control study, between 2008 and 2013. Sociodemographic, lifestyle and environmental factors were assessed in face-to-face interviews. Antibody responses to four EBV proteins (EBNA-1, ZEBRA, EA-D, and VCA-p18) were analyzed by multiplex serology. Odds ratios (OR) and 95% confidence intervals were calculated by using logistic regression mixed models to evaluate the association of seropositivity and antibody reactivity against EBV proteins with GC, adjusting for GC risk factors. Stratified analyses by tumor location (cardia vs. non-cardia) and morphology (intestinal vs. diffuse) were done. Among controls, seropositivity for EA-D, ZEBRA, EBNA-1 and VCA-p18 was 85%, 91%, 97% and 99%, respectively. Even though seropositivity for none of the studied proteins was associated with a higher GC risk, increasing antibody reactivity against EBNA-1 and VCA-p18 was associated with higher OR of GC. This association was present for cardia and non-cardia cancer cases, and for intestinal and diffuse types. Our results support the hypothesis that EBV may play a role in GC etiology, and highlight the importance of evaluating specific antibodies and the dose-response relations when studying widespread infections.

Sections du résumé

BACKGROUND
In contrast to the recognized role of Helicobacter pylori in the etiology of non-cardia gastric cancer (GC), there is still insufficient epidemiological evidence for the involvement of Epstein-Barr virus (EBV) in gastric carcinogenesis. We aimed to evaluate the relation of antibody profile and antibody reactivity intensity against four individual EBV proteins to GC risk.
METHODS
We used information from 281 GC cases and 2071 age and sex frequency matched controls recruited in the frame of the MCC-Spain multicase-control study, between 2008 and 2013. Sociodemographic, lifestyle and environmental factors were assessed in face-to-face interviews. Antibody responses to four EBV proteins (EBNA-1, ZEBRA, EA-D, and VCA-p18) were analyzed by multiplex serology. Odds ratios (OR) and 95% confidence intervals were calculated by using logistic regression mixed models to evaluate the association of seropositivity and antibody reactivity against EBV proteins with GC, adjusting for GC risk factors. Stratified analyses by tumor location (cardia vs. non-cardia) and morphology (intestinal vs. diffuse) were done.
RESULTS
Among controls, seropositivity for EA-D, ZEBRA, EBNA-1 and VCA-p18 was 85%, 91%, 97% and 99%, respectively. Even though seropositivity for none of the studied proteins was associated with a higher GC risk, increasing antibody reactivity against EBNA-1 and VCA-p18 was associated with higher OR of GC. This association was present for cardia and non-cardia cancer cases, and for intestinal and diffuse types.
CONCLUSION
Our results support the hypothesis that EBV may play a role in GC etiology, and highlight the importance of evaluating specific antibodies and the dose-response relations when studying widespread infections.

Identifiants

DOI: 10.1016/j.canep.2019.05.008 PMID: 31154081
pubmed: 31154081
pii: S1877-7821(19)30049-9
doi: 10.1016/j.canep.2019.05.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-88

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Nuria Aragonés (N)

Epidemiology Section, Public Health Division, Department of Health of Madrid, C/San Martín de Porres, 6, 28035, Madrid, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Nerea Fernández de Larrea (N)

National Center of Epidemiology, Carlos III Health Institute, Avenida Monforte de Lemos, 5, 28029, Madrid, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain. Electronic address: nfernandez@isciii.es.

Roberto Pastor-Barriuso (R)

National Center of Epidemiology, Carlos III Health Institute, Avenida Monforte de Lemos, 5, 28029, Madrid, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Angelika Michel (A)

Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

Beatriz Romero (B)

Department of Microbiology, Hospital Universitario Ramón y Cajal and Ramón y Cajal Health Research Institute (IRYCIS), Carretera de Colmenar Viejo, km. 9,100, 28034, Madrid, Spain.

Michael Pawlita (M)

Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

Sara Mayorgas-Torralba (S)

Department of Preventive Medicine and Public Health, Hospital Universitario Rey Juan Carlos, C/Gladiolo, s/n, 28933, Móstoles, Madrid, Spain.

Vicente Martín (V)

The Research Group in Gene - Environment and Health Interactions (GIIGAS), Biomedicine Institute (IBIOMED), University of León, Vegazana Campus, s/n, 24071, León, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Victor Moreno (V)

Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), and ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via de l'Hospitalet, 199-203, 08908, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Gran Via de les Corts Catalanes, 585, 08007, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Delphine Casabonne (D)

Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, Gran Via de L'Hospitalet, 199-203, 08908, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Jesús Castilla (J)

Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, C/Leyre, 15, 31003, Pamplona, Navarra, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Guillermo Fernandez-Tardón (G)

University Institute of Oncology (IUOPA), University of Oviedo, Building "Santiago Gascón", 1st Floor. Campus of "El Cristo" B, 33006, Oviedo, Asturias, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Trinidad Dierssen-Sotos (T)

Department of Medical and Surgical Sciences, University of Cantabria - Marqués de Valdecilla Research Institute (IDIVAL), C/Cardenal Herrera Oria, s/n, 39011, Santander, Cantabria, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Rocío Capelo (R)

Natural Resources, Health and Environment Research Center (RENSMA), University of Huelva, Avenida de las Fuerzas Armadas, s/n, 21007, Huelva, Spain.

Dolores Salas (D)

Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), C/Micer Mascó, 31, 46010, Valencia, Spain; General Directorate Public Health, Valencian Community, Avenida de Cataluña, 21, 46020, Valencia, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Inmaculada Salcedo-Bellido (I)

Preventive Medicine and Public Health Department, Faculty of Medicine, University of Granada, Avenida de la Investigación, 11, 18071, Granada, Spain; Granada Health Research Institute (ibs.GRANADA). Complejo Hospitalario Universitario de Granada, Avenida de las Fuerzas Armadas, 2, 18014, Granada, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

María Dolores Chirlaque (MD)

Department of Epidemiology, Murcia Health Authority, IMIB-Arrixaca, Ronda de Levante, 11, 30008, Murcia, Spain; Department of Health and Social Sciences, University of Murcia, Avenida Teniente Flomesta, 5, 30003, Murcia, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Nicole Brenner (N)

Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

Manuela Pedraza (M)

Department of Oncology, Complejo Asistencial Universitario de León, Altos de Nava, s/n, 24071, León, Spain.

Xavier Bessa (X)

Department of Gastroenterology, Hospital del Mar, Dr. Aiguader, 88, 08003, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Dr. Aiguader, 88, 08003, Barcelona, Spain.

Beatriz Pérez-Gómez (B)

National Center of Epidemiology, Carlos III Health Institute, Avenida Monforte de Lemos, 5, 28029, Madrid, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Julia Butt (J)

Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

Manolis Kogevinas (M)

ISGlobal, Doctor Aiguader, 88, 08003, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Dr. Aiguader, 88, 08003, Barcelona, Spain; Pompeu Fabra University (UPF), Plaça de la Mercè, 10-12, 08002, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Rosa Del Campo (R)

Department of Microbiology, Hospital Universitario Ramón y Cajal and Ramón y Cajal Health Research Institute (IRYCIS), Carretera de Colmenar Viejo, km. 9,100, 28034, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Avenida Dr. Fedriani, s/n, 41071, Sevilla, Spain.

Silvia de Sanjosé (S)

Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, Gran Via de L'Hospitalet, 199-203, 08908, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Tim Waterboer (T)

Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

Marina Pollán (M)

National Center of Epidemiology, Carlos III Health Institute, Avenida Monforte de Lemos, 5, 28029, Madrid, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Epstein Barr virus antibody reactivity and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Epstein Barr virus antibody reactivity and...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus oncogènes › Infections à virus Epstein-Barr › Epstein Barr virus antibody reactivity and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Epstein Barr virus antibody reactivity and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Epstein Barr virus antibody reactivity and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Epstein Barr virus antibody reactivity and...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies de l'estomac › Tumeurs de l'estomac › Epstein Barr virus antibody reactivity and...